1. Home
  2. AMRC vs ANAB Comparison

AMRC vs ANAB Comparison

Compare AMRC & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ameresco Inc.

AMRC

Ameresco Inc.

HOLD

Current Price

$21.12

Market Cap

1.2B

ML Signal

HOLD

ANAB

AnaptysBio Inc.

HOLD

Current Price

$54.10

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AMRC
ANAB
Founded
2000
2005
Country
United States
United States
Employees
1601
N/A
Industry
Engineering & Construction
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.3B
IPO Year
2010
2015

Fundamental Metrics

Financial Performance
Metric
AMRC
ANAB
Price
$21.12
$54.10
Analyst Decision
Strong Buy
Buy
Analyst Count
8
12
Target Price
$37.88
$71.67
AVG Volume (30 Days)
439.7K
818.3K
Earning Date
05-04-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
91.02
EPS
N/A
N/A
Revenue
$1,769,928,000.00
$234,603,000.00
Revenue This Year
$10.71
N/A
Revenue Next Year
$9.07
$52.14
P/E Ratio
N/A
N/A
Revenue Growth
28.76
157.01
52 Week Low
$15.52
$17.11
52 Week High
$44.93
$73.30

Technical Indicators

Market Signals
Indicator
AMRC
ANAB
Relative Strength Index (RSI) 31.56 44.82
Support Level N/A $52.32
Resistance Level $33.98 $57.70
Average True Range (ATR) 1.20 4.55
MACD -0.17 -0.98
Stochastic Oscillator 3.12 24.72

Price Performance

Historical Comparison
AMRC
ANAB

About AMRC Ameresco Inc.

Ameresco Inc is an energy infrastructure solutions provider dedicated to helping customers reduce costs, enhance resilience, and decarbonize to net zero in the energy transition. Its comprehensive portfolio includes implementing smart energy efficiency solutions, upgrading aging infrastructure, and developing, constructing, and operating distributed energy resources. Its solutions range from upgrades to facility's energy infrastructure to the development, construction and operation of renewable energy plants combined with tailored financial solutions. Its segments include North America Regions, U.S. Federal, Renewable Fuels, Europe, and Others. The majority of the revenue is derived from North America Regions segment.

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

Share on Social Networks: